Guided Therapeutics

Guided Therapeutics PEG

PEG Ratio (Price/Earnings-to-Growth) of Guided Therapeutics (GTHP) as of Oct 18, 2026.

PEG

-

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Guided Therapeutics is 2026 - . PEG Ratio (Price/Earnings-to-Growth) of Guided Therapeutics was 2025 -0.12 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics Inc, with ticker GTHP and ISIN US40171F5017, is a health care company headquartered in Norcross, Georgia. The company has 6 employees and went public on July 1, 1997. Guided Therapeutics focuses on developing medical devices, particularly utilizing biophotonic technology for cancer detection. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device designed to detect cervical cancer and precancers. The LuViva device scans the cervix with light and analyzes the reflected and fluorescent light to provide results at the point of care. It serves as an alternative to conventional cervical cancer screening methods, targeting two main applications: as a screening tool and as a triage method for traditional screening processes. The company develops prototypes and conducts limited clinical studies using its biophotonic technology, which is central to its approach for detecting esophageal cancer. Guided Therapeutics operates within the health care sector and industry, with its website at https://www.guidedinc.com/. The company's current operational focus is on the development and marketing of the LuViva device, though it has also explored applications in esophageal cancer detection through biophotonic technology. Guided Therapeutics has a small workforce of six full-time employees, reflecting its current scale of operations. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Guided Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Guided Therapeutics

All Key Metrics — Guided Therapeutics